JAGX stock is up on a new license agreement

 

• Jaguar Health (JAGX) stock is rising higher on a new license agreement.
• The company acquired the U.S. license for “chemo mouth” treatment Gelclair.
• This treatment is already approved by the FDA.

Jaguar Health (NASDAQ:JAGX) stock is rocketing higher on Tuesday after the pharmaceutical company announced a new license for a chemo mouth treatment.

Jaguar Health is looking to treat chemo mouth, a side effect of chemotherapy, with Gelclair. This treatment already has approval from the U.S. Food and Drug Administration (FDA).

Jaguar Health is licensing Gelclair from U.K.-based Venture Life Group. The product is a gel that makes it easier for patients undergoing chemotherapy to eat, drink, swallow, speak and sleep.

https://investorplace.com/2024/04/why-is-jaguar-health-jagx-stock-up-44-today/